Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

B. H. O'Neil; A. J. Scott; W. W. Ma; S. J. Cohen; D. L. Aisner; A. R. Menter; M. A. Tejani; J. K. Cho; J. Granfortuna; A. L. Coveler; O. O. Olowokure; J. C. Baranda; M. Cusnir; P. Phillip; J. Boles; R. Nazemzadeh; M. Rarick; D. J. Cohen; J. Radford; L. Fehrenbacher; R. Bajaj; V. Bathini; P. Fanta; J. Berlin; A. J. McRee; R. Maguire; F. Wilhelm; M. Maniar; A. Jimeno; C. L. Gomes; W. A. Messersmith

doi:10.1093/annonc/mdw095

Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. FehrenbacherR. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, W. A. Messersmith

Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	1180
Number of pages	1
Journal	Annals of Oncology
Volume	27
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdw095
State	Published - Jun 18 2016

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdw095

Cite this

O'Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J., Coveler, A. L., Olowokure, O. O., Baranda, J. C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D. J., Radford, J., ... Messersmith, W. A. (2016). Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264. Annals of Oncology, 27(6), 1180. https://doi.org/10.1093/annonc/mdw095

Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264. / O'Neil, B. H.; Scott, A. J.; Ma, W. W. et al.
In: Annals of Oncology, Vol. 27, No. 6, 18.06.2016, p. 1180.

Research output: Contribution to journal › Comment/debate › peer-review

O'Neil, BH, Scott, AJ, Ma, WW, Cohen, SJ, Aisner, DL, Menter, AR, Tejani, MA, Cho, JK, Granfortuna, J, Coveler, AL, Olowokure, OO, Baranda, JC, Cusnir, M, Phillip, P, Boles, J, Nazemzadeh, R, Rarick, M, Cohen, DJ, Radford, J, Fehrenbacher, L, Bajaj, R, Bathini, V, Fanta, P, Berlin, J, McRee, AJ, Maguire, R, Wilhelm, F, Maniar, M, Jimeno, A, Gomes, CL & Messersmith, WA 2016, 'Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264', Annals of Oncology, vol. 27, no. 6, pp. 1180. https://doi.org/10.1093/annonc/mdw095

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR et al. Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264. Annals of Oncology. 2016 Jun 18;27(6):1180. doi: 10.1093/annonc/mdw095

@article{86c9bed57965416da60a176eb4820437,

title = "Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264",

author = "O'Neil, {B. H.} and Scott, {A. J.} and Ma, {W. W.} and Cohen, {S. J.} and Aisner, {D. L.} and Menter, {A. R.} and Tejani, {M. A.} and Cho, {J. K.} and J. Granfortuna and Coveler, {A. L.} and Olowokure, {O. O.} and Baranda, {J. C.} and M. Cusnir and P. Phillip and J. Boles and R. Nazemzadeh and M. Rarick and Cohen, {D. J.} and J. Radford and L. Fehrenbacher and R. Bajaj and V. Bathini and P. Fanta and J. Berlin and McRee, {A. J.} and R. Maguire and F. Wilhelm and M. Maniar and A. Jimeno and Gomes, {C. L.} and Messersmith, {W. A.}",

year = "2016",

month = jun,

day = "18",

doi = "10.1093/annonc/mdw095",

language = "English (US)",

volume = "27",

pages = "1180",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Erratum

T2 - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

AU - O'Neil, B. H.

AU - Scott, A. J.

AU - Ma, W. W.

AU - Cohen, S. J.

AU - Aisner, D. L.

AU - Menter, A. R.

AU - Tejani, M. A.

AU - Cho, J. K.

AU - Granfortuna, J.

AU - Coveler, A. L.

AU - Olowokure, O. O.

AU - Baranda, J. C.

AU - Cusnir, M.

AU - Phillip, P.

AU - Boles, J.

AU - Nazemzadeh, R.

AU - Rarick, M.

AU - Cohen, D. J.

AU - Radford, J.

AU - Fehrenbacher, L.

AU - Bajaj, R.

AU - Bathini, V.

AU - Fanta, P.

AU - Berlin, J.

AU - McRee, A. J.

AU - Maguire, R.

AU - Wilhelm, F.

AU - Maniar, M.

AU - Jimeno, A.

AU - Gomes, C. L.

AU - Messersmith, W. A.

PY - 2016/6/18

Y1 - 2016/6/18

UR - http://www.scopus.com/inward/record.url?scp=84974794159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974794159&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw095

DO - 10.1093/annonc/mdw095

M3 - Comment/debate

AN - SCOPUS:84974794159

SN - 0923-7534

VL - 27

SP - 1180

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -

Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this